These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 31678470)

  • 1. Health-related quality of life measures and immune checkpoint inhibitors: A systematic review.
    Walocko FM; Ly BC; White MS; Chen SC; Yeung H
    J Am Acad Dermatol; 2020 Apr; 82(4):1004-1006. PubMed ID: 31678470
    [No Abstract]   [Full Text] [Related]  

  • 2. Immune-related cutaneous adverse events: A new opportunity for allergists and clinical immunologists.
    Leung DYM
    Ann Allergy Asthma Immunol; 2021 Jun; 126(6):607. PubMed ID: 34049668
    [No Abstract]   [Full Text] [Related]  

  • 3. Dermatology consultation reduces interruption of oncologic management among hospitalized patients with immune-related adverse events: A retrospective cohort study.
    Chen ST; Molina GE; Lo JA; Durbin S; Cohen JV; Reynolds KL; Kroshinsky D
    J Am Acad Dermatol; 2020 Apr; 82(4):994-996. PubMed ID: 31560981
    [No Abstract]   [Full Text] [Related]  

  • 4. Immune-related cutaneous adverse events due to checkpoint inhibitors.
    Wang E; Kraehenbuehl L; Ketosugbo K; Kern JA; Lacouture ME; Leung DYM
    Ann Allergy Asthma Immunol; 2021 Jun; 126(6):613-622. PubMed ID: 33609771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune-related dermatologic toxicities: to make a long story short.
    Angelaki A; Lampropoulou DI; Aravantinos G
    Cutan Ocul Toxicol; 2020 Mar; 39(1):10-12. PubMed ID: 31648558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tattoo Reactions Associated with Targeted Therapies and Immune Checkpoint Inhibitors for Advanced Cancers: A Brief Review.
    Kluger N
    Dermatology; 2019; 235(6):522-524. PubMed ID: 31387093
    [No Abstract]   [Full Text] [Related]  

  • 7. Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer.
    Suarez-Almazor ME; Kim ST; Abdel-Wahab N; Diab A
    Arthritis Rheumatol; 2017 Apr; 69(4):687-699. PubMed ID: 28085999
    [No Abstract]   [Full Text] [Related]  

  • 8. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
    Sibaud V
    Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic consequences of immune checkpoint inhibitors: A new challenge in clinical practice.
    Parthymos I; Liamis G; Dounousi E; Pentheroudakis G; Mauri D; Zarkavelis G; Florentin M
    Crit Rev Oncol Hematol; 2020 Jul; 151():102979. PubMed ID: 32480349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life.
    Joshi SS; Ortiz S; Witherspoon JN; Rademaker A; West DP; Anderson R; Rosenbaum SE; Lacouture ME
    Cancer; 2010 Aug; 116(16):3916-23. PubMed ID: 20564072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cochleovestibular toxicity induced by immune checkpoint inhibition: a case series.
    Lemasson J; Cuzzubbo S; Doucet L; Gounant V; Baroudjian B; Herms F; Carpentier AF; Lebbé C; Vitaux H; Hautefort C; Delyon J;
    Eur J Cancer; 2019 Aug; 117():116-118. PubMed ID: 31279302
    [No Abstract]   [Full Text] [Related]  

  • 12. Immune checkpoint inhibitors and cardiovascular toxicity.
    Lyon AR; Yousaf N; Battisti NML; Moslehi J; Larkin J
    Lancet Oncol; 2018 Sep; 19(9):e447-e458. PubMed ID: 30191849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac Toxicity of Immune Checkpoint Inhibitors: Cardio-Oncology Meets Immunology.
    Varricchi G; Galdiero MR; Tocchetti CG
    Circulation; 2017 Nov; 136(21):1989-1992. PubMed ID: 29158212
    [No Abstract]   [Full Text] [Related]  

  • 14. [Assessment of the quality of life of patients in dermatology].
    Iliev D; Furrer L; Elsner P
    Hautarzt; 1998 Jun; 49(6):453-6. PubMed ID: 9675571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Predictors of Nivolumab-Induced Skin Reactions].
    Osawa T; Inoue S; Umeda M; Hasegawa T; Makino T; Hori A; Tanaka K; Yasuda M; Mizui T; Sawa T; Sugiyama Y; Goto C
    Gan To Kagaku Ryoho; 2018 Oct; 45(10):1533-1535. PubMed ID: 30382069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Skin Reactions to Immune Checkpoint Inhibitors.
    Patel AB; Pacha O
    Adv Exp Med Biol; 2020; 1244():235-246. PubMed ID: 32301018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade.
    Postow MA; Sidlow R; Hellmann MD
    N Engl J Med; 2018 Jan; 378(2):158-168. PubMed ID: 29320654
    [No Abstract]   [Full Text] [Related]  

  • 18. ePROs in the follow-up of cancer patients treated with immune checkpoint inhibitors: a retrospective study.
    Iivanainen S; Alanko T; Peltola K; Konkola T; Ekström J; Virtanen H; Koivunen JP
    J Cancer Res Clin Oncol; 2019 Mar; 145(3):765-774. PubMed ID: 30666409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.
    Conforti F; Pala L; Bagnardi V; De Pas T; Martinetti M; Viale G; Gelber RD; Goldhirsch A
    Lancet Oncol; 2018 Jun; 19(6):737-746. PubMed ID: 29778737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Checkpoint inhibitors, the perspectives for elderly patients].
    Landre T; Karaoud F; Taleb C
    Soins Gerontol; 2017; 22(127):30-33. PubMed ID: 28917334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.